Shares of Abivax (NASDAQ: ABVX) were up more than 40% in the month ending July 6, after the company announced positive results from its late-stage (Phase 3) trial of its lead candidate, Obefazimod, which is being designed as a long-term maintenance treatment for ulcerative colitis (UC). The rally pushed ABVX nearly to its all-time high of $146.41, set in December 2025.
The 40% move wasn't a single, straight-line reaction to the clinical trial results. Instead, it reflects two distinct catalysts hitting in succession.
